CHAIR
:
Robert J. More, Partner, Domain Associates
SPEAKER
(S):
Jay Lichter, Ph.D., President and CEO, Akesis Pharmaceuticals
Scott D. Cormack, President & CEO, OncoGenex Technologies
Rajesh Shrotriya, MD, President & CEO, Spectrum Pharmaceuticals
Steven Kelly, CEO, Myomo
Description
Has the heyday of the fully integrated biopharmaceutical company passed? This panel will discuss the strategic decisions biotech companies make to add value, mitigate risk and bring treatments for life-threatening diseases to patients faster and cheaper than the traditional life sciences company.
Objectives:
Learn out-of-the box business strategies that biotech companies can pursue to reduce risk for their investors, employees and other stakeholders.
Learn recent trends in risk-mitigated drug development.
Learn to manage drug development and marketing with minimal overhead and infrastructure.